Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs.
Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections. Destiny says hese formulations will form the basis of XF drug delivery for its pre-clinical and clinical programs and treatments for both acute and chronic infections. Selected formulations will also be incorporated into ongoing grant funded projects including the Company’s UK-China AMR, Innovate UK grant funded collaboration, as announced last year.
“We are pleased to announce positive progress made to develop new formulations of XF drugs from our novel antimicrobial XF‐platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance,” Neil Clark, CEO of Destiny Pharma, comments. “We look forward to continuing to work with MedPharm to support the expansion of our pipeline as we take select formulations into our ongoing pre‐clinical and clinical studies. Our lead drug candidate from the XF-platform, XF‐73 nasal gel, for the prevention of post‐surgical infections, is currently in Phase 2b development with data expected in mid-2020.”
MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using in vitro models to de‐risk development programs.